Bill Search

  • Introduced
    Jan 22, 2021
  • Passed Senate
    May 26, 2021
  • Passed House
  • Signed into Law
Did you know we offer free bill tracking in Congress and 50 states, and a great mobile app? Sign up here
SB 262
Connecticut Senate Bill
AN ACT REQUIRING MANUFACTURERS OF BRAND NAME PRESCRIPTION DRUGS TO PROVIDE SAMPLES OF SUCH DRUGS TO MANUFACTURERS OF GENERIC PRESCRIPTION DRUGS. To promote competition in the prescription drug market by allowing developers of generic drugs and biosimilar products to obtain reference samples.
Last Action
House • May 27, 2021: House Calendar Number 554
Latest bill text
Do you support this bill?
Yay Nay

Official Summary/Bill Text

Comments on Bill

Tweets

Whip Lists

Sponsors:
Votes
Actions
  • May 27, 2021 | House
    • Favorable Report, Tabled for the Calendar, House
    • House Calendar Number 554
  • May 26, 2021 | Senate
    • Senate Passed
  • May 18, 2021 | Senate
    • Filed with Legislative Commissioners' Office
    • Reported Out of Legislative Commissioners' Office
    • No New File by Committee on Appropriations
    • Favorable Report, Tabled for the Calendar, Senate
  • May 17, 2021 | Senate
    • Joint Favorable
  • May 12, 2021 | Senate
    • Referred by Senate to Committee on Appropriations
  • May 04, 2021 | Senate
    • Filed with Legislative Commissioners' Office
    • Reported Out of Legislative Commissioners' Office
    • No New File by Committee on Judiciary
    • Favorable Report, Tabled for the Calendar, Senate
  • May 03, 2021 | Senate
    • Joint Favorable
  • Apr 28, 2021 | Senate
    • Referred by Senate to Committee on Judiciary
  • Mar 04, 2021 | Senate
    • Reported Out of Legislative Commissioners' Office
    • Favorable Report, Tabled for the Calendar, Senate
    • Senate Calendar Number 48
    • File Number 12
  • Feb 26, 2021 | Senate
    • Referred to Office of Legislative Research and Office of Fiscal Analysis 03/03/21 5:00 PM
  • Feb 17, 2021 | Senate
    • Filed with Legislative Commissioners' Office
  • Feb 16, 2021 | Senate
    • Joint Favorable
  • Jan 25, 2021 | Senate
    • Public Hearing 01/28
  • Jan 22, 2021 | Senate
    • Referred to Joint Committee on General Law